Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

All amounts are in U.S. dollars

QUEBEC CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and the full year ended December 31, 2008.

    2008 Highlights

    - February

      - First patients treated with AEZS-108 for a Phase 2 trial in advanced
        ovarian and endometrial cancers.

    - March

      - Patient dosing commenced with cetrorelix in the second efficacy study
        of the Phase 3 program in benign prostatic hyperplasia ("BPH").
      - Completion of the sale to Paladin Labs of the marketed product,
        Impavido(R) (miltefosine), for approximately $9.2 million.

    - April

      - Appointment of Juergen Ernst, as Interim President and CEO, the
        Company's Chairman of the Board at the time, following the departure
        of our former President and CEO;
      - Completion of patient recruitment for the first efficacy study of the
        Phase 3 program in BPH with cetrorelix.

    - May

      - First patients treated with cetrorelix for the safety trial of the
        Phase 3 program in BPH.

    - June

      - Completion of the sale of the Company's Quebec City property for a
        purchase price of $7.1 million.

    - September

      - Appointment of Juergen Engel, Ph.D., as Company President and CEO,
        succeeding Juergen Ernst who, at the same time, was appointed as
        Executive Chairman of the Company.

    - October and November

      - Completion of patient recruitment for the second efficacy trial of
        the Phase 3 program with cetrorelix in BPH.

      - Initiation of the second stage of patient recruitment for AEZS-108
        P
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/1/2015)... Md. , May 1, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... the $28.5 million second tranche of a $40 million ... Woodford first invested $25 million in NW ... Woodford entered into an agreement with the Company for ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... Professor Harry Dorn has developed a new area of fullerene ... semiconductors and quantum computing applications. , Dorn plays with ... are tinker toys. First, in 1999, he figured out how ... do it reliably, how to change the number of atoms ...
... (Nasdaq: PRXL ), a leading global biopharmaceutical ... the,first quarter of Fiscal Year 2009 (ending September ... conjunction with the successful completion of the,acquisition of ... Josef von Rickenbach, Chairman and Chief Executive Officer ...
... Annual Meeting, FREMONT, Calif., Sept. 8 Vermillion, ... today that a,team of scientists at Stanford University and ... the Annual General Meeting of the,PAD Coalition. Led by ... T.,Fung, Chief Scientific Officer at Vermillion, Inc., the research ...
Cached Biology Technology:Carbon molecule with a charge could be tomorrow's semiconductor 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Nanoparticle films are no longer a delicate matter: Vanderbilt ... so they don,t disintegrate at the slightest touch. In ... to create nanoparticles ultrafine particles with diameters less than ... of different methods to mold them into thin films which ...
... that a new colon cancer screening technique created by ... it could potentially be as or more successful than ... technique uses optical technology, called low-coherence enhanced backscattering (LEBS) ... of the rectum. Light shines on the tissue, scatters, ...
... Sustainable Energy Technologies was chosen for multiple reasons: to ... change, to provide society with security of energy supply ... For this a European graduate school is thought to ... of thought, to foster the development of excellent young ...
Cached Biology News:Researchers create freestanding nanoparticle films without fillers 2Researchers create freestanding nanoparticle films without fillers 3Colon cancer screening technique shows continued promise in new study 2
... and finishing services are tailored to ... large-scale 5' screening or full length ... experience with large-scale genome projects and ... ideal cDNA outsourcing solution. In addition, ...
... Agencourt offers quick turnaround sequencing of individual ... and high copy plasmids. Agencourt's world-class, high ... Phred20 bases per day. The key ... service are 24 48 hour sample ...
Great for biotinylating DNA/RNA probes...
...
Biology Products: